Please sign in to follow a disease.
Stemline Therapeutics, Inc.
Clinical trials sponsored by Stemline Therapeutics, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill shows promise for advanced breast cancer in early trial Results expected Nov 2026 (estimated)
- New hope for breast cancer patients with brain tumors: drug combo trial underway Results expected Dec 2026 (estimated)
- New drug cocktails aim to stall metastatic breast cancer Results expected Dec 2026 (estimated)
- Can chemotherapy tame a rare blood cancer? a look back at Real-World outcomes Results expected May 2027 (estimated)
-
New hope for older leukemia patients: targeted combo shows promise
Disease control OngoingThis study is for adults with a specific type of acute myeloid leukemia (CD123+ AML) who cannot receive standard strong chemotherapy. It tests a new drug, tagraxofusp, added to two other drugs (venetoclax and azacitidine) to see if it helps more people achieve complete remission.…
Phase 2 • Sponsor: Stemline Therapeutics, Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug cocktails aim to stall metastatic breast cancer
Disease control OngoingThis study tests a drug called elacestrant combined with other medicines in people with a common type of advanced breast cancer (ER+/HER2-). The goal is to find safe doses and see if these combinations can slow down cancer growth. About 435 adults with metastatic breast cancer wi…
Phase 1/2 • Sponsor: Stemline Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New pill shows promise for advanced breast cancer in early trial
Disease control OngoingThis Phase 2 trial tests the drug elacestrant in 61 people with estrogen receptor-positive, HER2-negative metastatic breast cancer who have not previously used CDK4/6 inhibitors. Participants take a daily pill for about 6 months. The study aims to see if the drug can delay cancer…
Phase 2 • Sponsor: Stemline Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC